Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00058201|
Recruitment Status : Completed
First Posted : April 9, 2003
Last Update Posted : December 18, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective, or whether chemotherapy is more effective than observation, in treating pancreatic cancer after surgery.
PURPOSE: Phase III trial to compare the effectiveness of two chemotherapy regimens with no further therapy in treating patients who have completely resected pancreatic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: fluorouracil Drug: gemcitabine hydrochloride Drug: leucovorin calcium Other: clinical observation||Phase 3|
- Compare the efficacy of adjuvant gemcitabine vs fluorouracil and leucovorin calcium (vs observation only in patients with ampullary or other pancreatic malignancy), in terms of overall survival, in patients with completely resected pancreatic cancer.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life and 5-year survival of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histology (ductal adenocarcinoma vs ampullary or other pancreatic malignancy), resection margin status, and participating country. Patients are randomized to 1 of 2 treatment arms. Randomization for patients with ampullary or other pancreatic malignancy includes an observation arm.
- Arm I: Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
- Arm III (patients with ampullary or other pancreatic malignancy only): Patients undergo observation.
Treatment in arms I and II repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, 3, 6, and 12 months, and then annually for 5 years.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 1,030 patients with pancreatic adenocarcinoma (515 per arms I and II) will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1030 participants|
|Official Title:||European Study Group For Pancreatic Cancer - Trial 3|
|Study Start Date :||July 2001|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||September 2010|
Active Comparator: Arm I
Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
Drug: leucovorin calcium
Experimental: Arm II
Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
Drug: gemcitabine hydrochloride
No Intervention: Arm III
Patients undergo observation.
Other: clinical observation
- Overall survival
- Toxicity as measured by NCI CTC v2.0
- Quality of life as measured by EORTC QLQ C-30 and ESPAC-QLQ at 3, 6, and 12 months, and then annually for 5 years
- Survival rate at 2 and 5 years
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00058201
Hide Study Locations
|Australia, New South Wales|
|Institute of Oncology at Prince of Wales Hospital|
|Randwick, New South Wales, Australia, 2031|
|Australia, South Australia|
|Flinders Medical Centre|
|Bedford Park, South Australia, Australia, 5042|
|Cross Cancer Institute at University of Alberta|
|Edmonton, Alberta, Canada, T6G 1Z2|
|Canada, British Columbia|
|British Columbia Cancer Agency - Centre for the Southern Interior|
|Kelowna, British Columbia, Canada, V1Y 5L3|
|British Columbia Cancer Agency - Vancouver Island Centre|
|Victoria, British Columbia, Canada, V8R 6V5|
|Winnipeg, Manitoba, Canada, R3E 0V9|
|Canada, Nova Scotia|
|Nova Scotia Cancer Centre|
|Halifax, Nova Scotia, Canada, B3H 1V7|
|Cancer Research Institute at Queen's University|
|Kingston, Ontario, Canada, K7L 3N6|
|Cancer Centre of Southeastern Ontario at Kingston General Hospital|
|Kingston, Ontario, Canada, K7L 5P9|
|London Regional Cancer Program at London Health Sciences Centre|
|London, Ontario, Canada, N6A 4L6|
|Ottawa Hospital Regional Cancer Centre - General Campus|
|Ottawa, Ontario, Canada, K1H 8L6|
|Edmond Odette Cancer Centre at Sunnybrook|
|Toronto, Ontario, Canada, M4N 3M5|
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2M9|
|St. Joseph's Health Centre - Toronto|
|Toronto, Ontario, Canada, M6R 1B5|
|Hopital Charles Lemoyne|
|Greenfield Park, Quebec, Canada, J4V 2H1|
|McGill Cancer Centre at McGill University|
|Montreal, Quebec, Canada, H2W 1S6|
|Institute for Clinical and Experimental Medicine|
|Preha 4, Czech Republic, 14021|
|Tampere University Hospital|
|Tampere, Finland, 33521|
|Paris, France, 75970|
|Heidelberg, Germany, D-69120|
|Agia Olga Hospital|
|Athens, Greece, G-15233|
|Petz Aladar County Hospital|
|Gydr, Hungary, h-9024|
|Policlinico Borgo Roma|
|Verona, Italy, 37134|
|Kyoto University Hospital|
|Kyoto, Japan, 606-8507|
|Uppsala University Hospital|
|Uppsala, Sweden, S-75185|
|Bern, Switzerland, CH-3010|
|Royal Liverpool University Hospital|
|Liverpool, England, United Kingdom, L69 3GA|
|Study Chair:||John P. Neoptolemos, MD||Royal Liverpool University Hospital|
|Study Chair:||Malcolm J. Moore, MD||Princess Margaret Hospital, Canada|
|OverallOfficial:||R. Padbury||Flinders Medical Centre|
|OverallOfficial:||David Goldstein, MD||Institute of Oncology at Prince of Wales Hospital|